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SUMMARY 
 Starting from the late 2000s the validity of the medicinal products became one of the 
most important issues to be considered, as the level of falsified medicinal products sales 
significantly increased. In order to solve this issue, the Directive 2011/62 / EC (3) on falsified 
medicinal products for human use was introduced and now serves as a basis for the 
distribution of medicinal products, which only allows licensed pharmacies and approved 
retailers, including approved Internet service providers, to be included into the movement of 
the product. This directive introduced safety signs aimed at preventing the entry of falsified 
medicinal products into the supply chain of legal medicinal products (from the manufacturer 
to distributors, pharmacies and hospitals) and, consequently, to the patients. It is important 
that patients can recognize reliable sources and be aware of the risk of illegal sales. It is 
interesting to note that in the EU not only a two-dimensional code will be used to track 
individual packages of medicinal products, but also an unauthorized opening indicator, since 
in the absence of an indicator only the package is actually traced, but not its contents. 
Characteristically, the regulations harmoniously fit into both European and International 
regulation. In addition, the regulation prescribes encryption into a unique identifier of 
medicinal product the information described using a standardized international nomenclature, 
which will serve not only the objectives of traceability and protection against falsification, but 
also improve the collection of pharmaco-epidemiological and pharmacovigilance data. The 
new regulation contains other norms that allow a better understanding of the problems of 
traceability and their development in the EU. It is emphasized that all prescription medicinal 
products registered in the country and some non-prescription ones (right now only one - 
Omeprazol), must be labelled with a unique identifier by the manufacturer. The main idea of 
the traceability mechanism in the EU is the practice of "step back - step forward".  
Consequently, the new regulation also introduced new obligations for wholesalers, 
which concern standards in the quality system, personnel training and hygiene, facilities and 
equipment, documentation, thus updating the Good Distribution Practice. Implementation of 
this system in Latvia required improvement in the IT infrastructure, which resulted in 
signifcant costs for manufacturers, distributors and pharmacy chains. Regulatory access to the 
database is also a separate aspect of the implementation of this project and had to be agreed at 
the initial stages.  
Moreover, in the first month when the regulation came in force, the European Union 
IT infrastructure was detected as not ready to perform correctly with given number of 
transactions and users, therefore the distributors and producers faced a number of problems 
when the scanned data were not displayed or verified correctly. This cases are repeating 
almost every week, urging the distributors to move the packages to the quarantine area and 
not being able either to return, or to sell the medicinal products, even despite the fact that the 
medicinal products are not falsified, are approved by laboratory, and even in case of the 
reimbursed medicines or medicines for the hospitals, that are urgently needed for patients in 
critical conditions. Trying to solve these issues the companies are usually reported that the 
problem is on the data repository level and the companies have to quarantine the product until 
a problem is solved. This occurs also due to the challenge for the manufacturers to report on 
the volume of production of medicines in advance and buy the unique codes for each batch 
from the European hub, which is not always possible in the conditions of market volatility and 
demand for it. Disregarding the fact that this issue was unpleasant, it was mostly solved by the 
producers and distributors, who have predicted the possibility of the failure and hedged the 
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risks by ordering, producing and importing the medicinal products before the 09th of 
February, to secure availability of necessary medicinal products on stock for one or two 
months ahead, until the IT issues would be solved. However, the drop in sales was already 
noted, as while the producers were trying to comply with the requirement they were not able 
to move the goods in a regular amount, therefore the financial ratios also dropped. 
Accordingly, a number of problematic situations in connection with the patient’s rights 
arise because of the quarantined medicines: first, medicinal products for patients from the 
reimbursement list are not available in a timely manner, though similar ones are available, but 
for money; secondly, medicinal products for hospitals, prisons and other social and state 
institutions responsible for treating the population are not available in a timely manner; 
thirdly, medicinal products, which should be delivered in time according to the public 
procurement contracts are also not available. In a given situation, a violation of a number of 
patients' rights occurs, as well as a conflict of interests and restriction of the distributor’s 
freedom. Violations of patient’s rights or lack of attention to them can have serious health 
consequences. Such type of a hidden discrimination in healthcare is a powerful barrier to 
access the health services and affects their quality.  
Summing up, given the positive impact of the new regulation for the patients’ and the 
overall situation, this regulation put the producers and distributors under additional pressure 
they have to deal with and also may negatively affect the patient’s rights.  
 
 
 
  
4 
 
TABLE OF CONTENTS 
SUMMARY ................................................................................................................................... 2 
TABLE OF CONTENTS ................................................................................................................... 4 
INTRODUCTION ............................................................................................................................ 5 
1. EUROPEAN UNION PREVENTION REGULATION OF THE ENTRY INTO THE LEGAL SUPPLY 
CHAIN OF FALSIFIED MEDICINAL PRODUCTS ................................................................................. 8 
1.1. Problem of the falsification of medicinal products for human use .............................. 8 
1.2. Background of the regulation aimed at prevention of distribution of the European 
Union 10 
1.3. Updated directive and delegated regulation of the European Union ......................... 12 
2. GOOD DISTRIBUTION PRACTICE FOR PHARMACEUTICAL COMPANIES: ORIGINS AND AIMS ... 15 
2.1. Current situation on the GDP in the pharmaceutical industry ................................... 15 
2.2. Updated duties of the pharmaceutical companies ...................................................... 16 
3. CASE ANALYSIS OF THE DISTRIBUTOR IN LATVIA ............................................................... 18 
4. POSSIBLE CONFLICTS AND PROBLEMS DURING THE IMPLEMENTATION OF THE NEW FALSIFIED 
MEDICINAL PRODUCTS’ DISTRIBUTION PREVENTION REGULATION ............................................. 21 
4.1. Challenges pharmaceutical companies and another distributors face........................ 21 
4.2. Legal conflicts ............................................................................................................ 22 
CONCLUSIONS ........................................................................................................................... 28 
BIBLIOGRAPHY .......................................................................................................................... 31 
 
5 
 
INTRODUCTION 
After the 2010 the European institutions have been widely reporting an alarming 
increase in the number of medicinal products containing poor quality ingredients or 
counterfeit ingredients that do not contain active ingredients or contain them in the wrong 
dosage (too high or too low), considering this a threat to the patient health as such and also 
the public health issue. These types of the medicinal products were widely concerned as 
falsified or counterfeit and create a risk, that the disease with this product will not be treated 
or the adverse outcome and severe side effect will occur. Moreover, the interaction with this 
medicine with other medicinal products or medicinal devices that patient is using on a regular 
basis is unpredictable and can endanger the life and health. This is due to the fact the falsified 
medicine usually is not controlled or regulated by the safety or quality standards, that are 
presented by the regulatory authority of the country in compliance with the EU registration 
procedures
1
. 
It is suggested that patients should be aware of the risks, that might be created by the 
illegal sales and usage of the falsified medicinal products and support the relationships 
between the producers and patient, protecting all of them via creating the binding legislation 
on this point. Consequently, the Directive 2011/62 / EC (3) 
2
on falsified medicinal products 
for medical use was created in the way to serve as a basis for the distribution of medicinal 
products. The new legislation created a path that allowed a limited number of representatives 
of industry (e.g. only licensed pharmacies) to be included into the medicinal products’ supply 
chain. It is important, that the new legislative framework introduced safety signs aimed at 
preventing the entry of falsified medicinal products into the supply chain of legal medicinal 
products (from the manufacturer to distributors, pharmacies and hospitals) and, consequently, 
to the patients. Patient rights’ protection organizations in connection with other institution 
have to raise awareness by informing patients and increasing the safety of medicinal 
products
3
.  
Still, during the implementation of the new regular framework, a big pressure was 
putted on the retailers and other institutions. The essence of this innovation lies in the fact that 
the unique number of each pack will allow one to track and identify medicinal products in real 
time throughout the entire chain of medicinal products: manufacturer - distributor - pharmacy 
or hospital. The last phase of the Directive came into force on February 9, 2019. From this 
point on, prescription medicinal products that are sold in the EU must have a serial number, a 
two-dimensional code and protection from the first opening. All products that were approved 
for sale before February 9, 2019, may be in circulation before the expiration date or before the 
patient purchases it (whichever comes first). Manufacturers will enter the information 
contained in a unique identifier for each individual medicine in the EU central database, that 
                                                          
1 European Commision. New safety features for medicines sold in the EU - Questions & Answers, Available on 
http://europa.eu/rapid/press-release_MEMO-19-802_en.htm. Accessed June 04, 2019. 
2
 Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 
2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of 
the entry into the legal supply chain of falsified medicinal products Text with EEA relevance, OJ L 174, 
1.7.2011, pp. 74–87  
3 European Commision. New safety features for medicines sold in the EU - Questions & Answers, Available on 
http://europa.eu/rapid/press-release_MEMO-19-802_en.htm. Accessed June 04, 2019. 
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is a part of a comprehensive drug testing system, introduced by the new legislation. 
Depending on the origin of the medicinal product, the wholesalers might also need to scan the 
medicinal products during its movement through the chain to verify its origin and batch, as 
well as pharmacies (even in hospitals) will have to do the same before dispensing the 
medicinal product to the patient
4
. To date, the main difficulties in dealing with counterfeit 
medicinal products are associated, firstly, with the fact that it is almost impossible to 
determine the real extent of their circulation in the market, since official statistics only reflect 
the number of detected counterfeit medicinal products. Secondly, the manufacturing 
techniques of counterfeit are improving every year, therefore, it is possible to distinguish a 
genuine product from a fake, only having special knowledge, experience and technologies. 
Thus, the only way to combat fraud is to take cardinal preventive measures that can not only 
make counterfeiting a non-profitable and unattractive business, but also completely exclude 
the possibility of falsifying original medicinal products. These measures should include the 
improvement of law enforcement agencies effectiveness in identifying and preventing the 
circulation of counterfeit medicinal products, toughening the responsibility for their 
production and circulation, modification of criminal legislation, and further improvement of 
legislation. However, the transfer from one system of control to another can put additional 
pressure to the producers and distributors, as well as endanger the patients’ rights.  
The aim of this paper is to analyse the impact of new falsified medicinal products’ 
distribution prevention regulation on distributors and patients’ rights in Latvia.  
 In order to reach the aim, the following tasks have been set up:  
 To analyse the literature review behind the problem of the falsification of the 
medicines.  
 To analyse the background and the introduced updates to the new falsified 
medicinal products’ distribution prevention regulation. 
 To analyse the good distribution practice issues and operations of the 
pharmaceutical companies.  
 To present the case analysis of the distributor in Latvia, based on the experience.  
 To present possible conflicts and challenges which appear after the 9th of February, 
when the new regulation came into force;  
 To drive conclusions about patients’ rights and falsified medicinal products’ 
distribution.  
Hypothesis of the thesis is as follows: implementation of the new falsified medicinal 
products’ distribution prevention regulation puts additional not reasonable economic pressure 
on the pharmaceutical companies and other distributors, as well as may be a basis for legal 
conflicts. 
Research questions of the thesis are as follows:  
[RQ1]: What are the background and benefits of the new European Union prevention 
regulation of the entry into legal supply chain of falsified medicinal products?   
[RQ2]: What are the updated or newly created duties of the pharmaceutical products 
distributors?  
                                                          
4
 European Patient’s Academy. Falsified medicines, Available on https://www.eupati.eu/safety-of-
medicines/falsified-medicines/. Accessed June 04, 2019. 
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[RQ3]: What are the conflicts and problems pharmaceutical products distributors face 
while implementing the new requirements set by the updated regulation?  
The research is descriptive by its nature, as well as the study is causal, establishing the 
cause-and-effect of new regulation coming into force. The study is non-contrived, while the 
researcher did not manipulate the variables. The study is longitudinal, while the author 
presents the changes in legislation over time. The research is qualitative, the researcher 
interference is minimal.  The study has some limitations, while the researcher had limited 
amount of time to study all the relevant legislative background, therefore used the major 
documents as well as summaries presented by other researchers.  
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1. EUROPEAN UNION PREVENTION REGULATION OF THE ENTRY INTO THE 
LEGAL SUPPLY CHAIN OF FALSIFIED MEDICINAL PRODUCTS 
Medicinal products’ falsification issue has been noted as long as the pharmacy has 
been transferred into a business. The limited terms of production, limited shelf life, and other 
features of the medicinal products for human use, made it economically profitable to produce 
and import the falsified medicinal products, while the falsified medicines usually possessed 
the shorter route from the production to the end user, making the financial cash flow turnover 
rapid. Moreover, the falsified products were also produced in rather small batches directly in 
the pharmacies, that made it almost invulnerable to the inspection of the regulatory 
authorities. Even more to add, if the falsified medicinal product for the human use did not 
create the expected therapeutic effect, it was always possible to refer to the fact that every 
patient reacts differently to the medicine. This tendency was supported by the free market as 
well as by the disparity between the real supply of the medicines for human use of different 
types and the effective demand for it. Often specific medicinal products, that are in high 
demand of the society, are either not available on the market due to the various political and 
economic reasons, while the own industry of the country is not developed and imports are not 
allowed or are not economically reasonable for the importer due to high regulatory 
requirements and registration costs, or the unreasonable customs duties, or due to inadequate 
pricing policy under the pressure of economic or political conditions, resulting in too high 
shelf prices, that are not acceptable for the mass market. In the modern economic conditions, 
the costs for overcoming the barriers or enter the market, creating the path of the medicinal 
products to the consumer, are often too high for the importer, that creates the certain 
opportunity for the producers of the falsified medicines. Usually the low price is the main 
cause of the immortality of true and imaginary falsifications of the products of all times. Still, 
the amounts of the falsified medicinal products for human use reached too high levels, leading 
to the World Health organisation to drive its attention to the case in the end of 20th century. In 
this chapter author presents the detailed analysis of causes for the falsification of the 
medicinal products for human use, as well as presents the background behind the new 
regulation of the European Union regarding the prevention of the entry into legal supply chain 
of falsified medicinal products for human use.   
1.1. Problem of the falsification of medicinal products for human use 
According to the World Health organisation there are three types of medicinal 
products for human use that may be defined as falsified. These are as follows:  
Substandard, that are also so-called «missing the specification» medicine, that are 
authorized, but still not completing one or more quality standards or specifications, mentioned 
in the registration dossier of the medicinal product. Registration dossiers, are the standards of 
each specific medicinal product, that has been officially approved by the regulatory authority. 
In case of European Union this institution is either European Medicines Agency (regional 
regulatory authority) or Medicines Agency of each member state (national regulatory 
authority).  
Unregistered or unlicensed medical products for human use that have not been either 
submitted or approved by European Medicines Agency (regional regulatory authority) or 
Medicines Agency of the member state (national regulatory authority) for the specific market 
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they have been marketed to. Sometimes it is subject to the national permit, then this permit 
has to be approved and referred to the national or regional regulatory authority.  
Falsified medical products for human use which fraudulently misrepresent 
composition, source, brand or identity. Falsified medicines are not counterfeit medicines, 
while counterfeit ones are medicinal products that do not comply with intellectual-property 
rights or that infringe trademark law. 
As soon as the unregistered medicines for the human use are sometimes the subject of 
the exception, the majority of the regulatory authorities were mainly concerning the 
substandard and falsified medicinal products as the “falsification”, that created the definite 
misunderstanding in the various countries and lead to the rise in the level of distribution of the 
products approved on one market to the markets they have not been licenced for. Let author 
next concern the typed of the falsified and substandard medicinal products and the problems 
caused by the distribution. First, one of the typed is the placebo medicinal products, that are 
marketed without any active substance, that is replaced by the neutral substance, like lime, 
talc and soda. These medicinal products do not have any impact of the condition of the end 
user. Second, medicinal products “imitators” appear, where the active substance is replaced 
by the other ingredient, that is less costly, but may have the other therapeutic impact or 
adverse reactions. This type of the medicinal products is dangerous for the health of the 
patient, while the unpredicted reaction might be caused. The third type includes those 
medicinal products for human use that contain the same active ingredient, only in a greater or 
lesser amount. It does not bring direct harm to the health of the end consumer, but the effect 
will be somewhat changed. Since cheap substances and excipients may be of poor quality, 
then a large amount of technological impurities (uncontrolled by the standards) with an 
unpredictable toxic effect may be present in the finished product formulation. Unknown 
composition and production technology of the falsified medicinal products can lead to the risk 
of non-bioequivalence (too fast or too slow release of the active substance, that can cause 
respectively overdose and adverse reactions or insufficient efficiency, form resistant strains of 
microorganisms (in the case of antimicrobial medicinal products). Summing up, any 
falsification of medicinal products for human use is considered a threat because the quality 
control due diligence has not been performed.  
The quality of the medicinal product is a set of properties that give the specific 
medicinal product for human use the ability to satisfy the end user (patient) in accordance 
with the purpose and comply with the requirements established by law. Usually, the quality of 
the medicinal product consists of three levels of compliances:  
The effectiveness and safety (similar to benefit/risk ratio) of the most active 
pharmaceutical ingredient. The doctor and the patient are aware of differences in the 
efficiency and make the choice when prescribing and buying the specific medicinal product. 
The requirements for the quality of the specification for the substance and finished 
medicinal product, as well as the level of development, production and quality control of the 
medicinal product (for example, compliance with the Good Manufacturing Practise 
requirements), which forms the difference in quality between different manufacturers of the 
same products, that affects the efficacy and safety. One of the main criteria for product 
specification quality check is the compliance of the medicinal product specification 
requirements with the requirements of the pharmacopoeia, which establishes the state quality 
standard for drugs. 
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The compliance of a specific sample of the medicinal product for human use with the 
requirements of its own specification (which is part of the registration dossier). The product 
that does not meet the requirements of its specification is considered substandard. Unlike the 
first two levels, the consumer is not aware of the compliance with the third level of quality, 
that created the possibility of falsification.  
The proposed classification demonstrates the complexity and ambiguity of the concept 
of the medicinal product quality due diligence control.  
In the end of 1984, the amounts of the falsified medicinal products for human use 
reached the enormous level, that is why in Nairobi in 1985, with the support of the WHO, 
took part the first worldwide Conference of Experts on the rational use of medicinal products. 
The aforementioned event was the first conference, where the national drug policies were 
discussed in details, as well as the procedures of changes, prescription practices, promotion 
and distribution had been discussed. Since then, the procedure of the introduction of the 
regulation regarding the prevention of distribution of falsified medicines has been actively 
introduced.  
WHO suggests that pharmaceutical industry has a crucial role in the control, detection 
and destruction of falsified medicines for human use, which, according to the World Health 
organisation, can be performed by the development of protection systems (protective labels) 
in the way, allowing to prevent the falsification of the products, as well as preservation of 
drugs and packaging materials warehouses from theft. Regular research of own and national 
distribution channels according to WHO is mandatory in order to detect falsifications. WHO 
emphasized, that it is necessary to urge medicines’ manufacturers who have been subjected to 
falsification to voluntarily disseminate such information through national authorized 
medicines quality control authorities and government officials, aimed at monitoring the 
compliance with laws in order to use it as an evidence in legal proceedings
5
.  
1.2. Background of the regulation aimed at prevention of distribution 
of the European Union 
The legal framework for the regulation of the medicinal products’ market was 
established in 1965 via the Council Directive 65/65/EEC of 26 January 1965 on the 
approximation of provisions laid down by law
6
, regulation or administrative action relating to 
medicinal products. In subsequent years, the legislation of the European Union actively 
developed through the adoption of dozens of other directives, decisions and resolutions of the 
governing bodies of the European Union, including the Council Directive 75/318/EEC of 20 
May 1975 on the approximation of the laws of Member States relating to analytical, 
pharmaco-toxicological and clinical standards and protocols in respect of the testing of 
proprietary medicinal products
7
, as well as a number of other provisions, that have been 
specifically introduced for the proprietary medicinal products, immunological medicinal 
                                                          
5
 World Health Organisation. Substandard and Falsified Medical Products, available on: 
https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products. Accessed April 
19, 2019. 
6
 Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, 
regulation or administrative action relating to medicinal products, OJ 22, 09.02.1965, pp. 369–373 
7
 Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to 
analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary 
medicinal products, OJ L 147, 9.6.1975, pp. 1–12 
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products consisting of vaccines, toxins or serums and allergens, medicinal products derived 
from human blood or human plasma. In the earliest 1990s some additional legislative 
framework has been introduced, like Council Directive 92/25/EEC of 31 March 1992 on the 
wholesale distribution of medicinal products for human use
8
, that was one of the first 
European Union documents, regarding the wholesaling of the products, as well as the Council 
Directive 92/26/EEC of 31 March 1992 concerning the classification for the supply of 
medicinal products for human use
9
.  The same time the regulations on the labelling, 
promotion and marketing have been introduced widening the scope of Directives 65/65/EEC 
and 75/319/EEC.  
At the beginning of the new century, the previously existing regulations were revised 
and replaced by a single code by the Directive 2001/83/EC of 6 November 2001
10
. The 
directive laid down all the fundamental principles of market entry (registration), production 
and pharmacovigilance of registered medicinal products, especially for human use. Exactly 
this directive created the basis for the existing updated regulation on the falsified medicinal 
products for human use, while it contained the fundamental standards for confirming safety 
and efficacy, as well as the need to prove a positive balance between the benefits and risks of 
a drug. The Directive contained all registration procedures including registration grounds 
(original / reference product, replicated, hybrid, biosimilar product, established drug use, 
fixed combination, and other), production issues and Good Manufacturing Practise issues, 
drug information issues (labelling), wholesaling and Good Distribution Practise issues, 
conditions for release, advertising, pharmacovigilance, as well as supervision and sanctions. 
Moreover, the appendix to the directive contained requirements for the dossier of medicinal 
products registered on a different legal basis, that was a first try to eliminate the risk of 
unregistered or unlicensed medical products for human use to be marketed on non-specified 
market. In addition, this Directive became more detailed, contained more clarifications and 
was more precisely written (and translated). It allowed a better interpretation of the European 
Union requirements.   
Still, as a result, there was a necessity on the even more detailed regulation of the 
medicinal products, that is why the Directive was amended step by step in the majority of the 
aspects, providing new grounds. Overall, it was amended by the following directives and 
regulations:  
 Directive 2002/98/EC of the European Parliament and of the Council of 27 
January  
 Commission directive 2003/63/EC of 25 June 2003 L 159 46 27.6.2003  
 Directive 2004/24/EC of the European Parliament and of the Council of 31 March  
 Directive 2004/27/EC of the European Parliament and of the Council of 31 March  
 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 
12 December 2006  
 Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 
13 November  
                                                          
8
 Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human 
use, OJ L 113, 30.4.1992, pp. 1–4 
9
 Council Directive 92/26/EEC of 31 March 1992 concerning the classification for the supply of medicinal 
products for human use, OJ L 113, 30.4.1992, pp. 5–7 
10
 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community 
code relating to medicinal products for human use, OJ L 311, 28.11.2001, pp. 67–128 
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 Directive 2008/29/EC of the European Parliament and of the Council of 11 March  
 Directive 2009/53/EC of the European Parliament and of the Council of 18 June 
2009  
 Commission Directive 2009/120/EC of 14 September 2009  
 Directive 2010/84/EU of the European Parliament and of the Council of 15 
December  
 Directive 2011/62/EU of the European Parliament and of the Council of 8 June  
 Directive 2012/26/EU of the European Parliament and of the Council of 25 
October 2012 
 Directive 2011/62/EU of the European Parliament and of the Council was the 
latest updated version devoted to the prevention of the falsified medicinal 
products’ for human use11, that created the ground for the modern regulations, 
which will be seen in the next subchapter.   
1.3. Updated directive and delegated regulation of the European 
Union 
In 2011, EU Directive No. 2011/62/EC was adopted to amend Directive No. 
2001/83/EC to ensure the safety of medicinal products and prevent falsifying
12
. In 2016, the 
Delegated Regulation 2016/161 was adopted, which is an addition to the Directive of the 
European Parliament No. 2001/83 / EC in the parts that have been amended by Directive No. 
2011/62/EC
13
. 
According to the documents, all EU member states are obliged to bring their own 
legislation and trade practices in line with the requirements of this directive until February 9, 
2019. It is important to note, while the updated requirements implied that protection against 
the falsification of the medicinal products is carried out by applying a special unique number 
on the packaging, which will allow to distinguish falsified medicinal products from the 
original ones, since the unique number of each package can be checked at any time using a 
special database on the European and national levels. The new regulation uses two-
dimensional codes that are designed to encode a large amount of information. The decoding 
of such a code is carried out in two dimensions (horizontally and vertically). It is emphasized 
that all prescription medicinal products registered in the country and some non-prescription 
ones (right now only one - Omeprazol), must be labelled with a unique identifier by the 
manufacturer. 
Germany was chosen as the country for the implementation of the pilot project, that 
was defined as successful. Moreover, in addition to the fact, that a package of the product 
must bear a unique serial number to identify and confirm the authenticity of each product, it 
must be also sealed in such a way that there are obvious marks on it when attempting to open 
it. 
                                                          
11
 Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 
2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of 
the entry into the legal supply chain of falsified medicinal products Text with EEA relevance, OJ L 174, 
1.7.2011, pp. 74–87  
12
 Ibid. 
13
 Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of 
the European Parliament and of the Council by laying down detailed rules for the safety features appearing on 
the packaging of medicinal products for human use (Text with EEA relevance), available on: https://emvo-
medicines.eu/new/wp-content/uploads/Delegated-Regulation-EU-2016-161.pdf. Accessed April 19, 2019. 
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Consequently, the details on which institutions are going to control authenticity of 
medicinal products and the way how it will be performed, as well as the characteristics of 
various protection options in the final version were published in the Delegated Regulation of 
the EU Commission 2016/161
14
. According to the Directive the serial numbers and the 
integrity of the package of the medicinal products are monitored at distribution points, at 
production and during the movement of the package. The serial numbers are checked vie the 
national database, and the integrity of the packaging is determined visually adding the 
requirements to the Good Distribution Practice guidelines. 
Pharmaceutical companies, their subcontractors, wholesalers and pharmacies were 
involved in the implementation of the solution. Falsified medicinal products have to be 
quickly detected and removed from traffic without incident. Manufacturers who do not have 
such a tracking solution will have to withdraw their products from the European market. The 
existing solution (proved in the test project) called Datamatrix stores a large amount of 
information in a small space, the potential of reading is better than a traditional barcode.  The 
tightening of regulations, dictated by the fight against falsification of medicinal products, 
requires measures of maximum security throughout the supply chain in the manufacture of 
pharmaceutical products. Serialization (meaning the check of all “series” or batcher of the 
medicinal products) for the purpose of reliable product tracking became the decisive means of 
ensuring quality and safety. Therefore, at each stage of production and packaging, medicinal 
products for human use are printed with data that allows them to track products along the 
chain from the manufacturer to the customer
15
. Similar initiatives are being implemented in 
pharmaceutical production in other countries of the world, for example, in the USA, China 
and Brazil, still in the majority of them are not yet fully implemented. Manufacturers of 
pharmaceutical products in these countries also must supply all products and packaging with 
unique traceable serial numbers.  
The main idea of the traceability mechanism in the EU is the practice of "step back - 
step forward". It is understood as a system in which each participant in the supply chain can 
provide information about the origin of the medicinal product and its further movement. Thus, 
producers and distributors themselves must control and identify to whom they supply and 
from whom they purchase products throughout the entire chain, updating the requirements of 
the Good Distribution Practice guidelines. 
In addition, on January 1, 2016, the European Convention called Medicrime entered 
into force, providing for criminal liability for falsifying and counterfeiting of medicinal 
products, their illegal production and similar crimes that pose a threat to public health. This 
convention is the first international document that obliges all signatories to bring to justice 
those responsible for the deliberate falsification of medicinal products, relevant documents, 
trade of the falsified products
16
.  
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2. GOOD DISTRIBUTION PRACTICE FOR PHARMACEUTICAL COMPANIES: 
ORIGINS AND AIMS 
The Good Distribution practice (GDP) is a quality assurance system for warehouses 
and wholesaler companies in the circulation of medicinal products. According to 
internationally accepted GDP rules, distributors of medicinal products must align their 
activities with these standards. The implementation of GDP rules ensures the availability of 
consistent quality management systems throughout the supply chain: starting with the 
delivery of raw materials to manufacturing plants and ending with the shipment of finished 
products to end customers. Independent assessment is the most effective way to confirm that 
the quality management system complies with international GDP requirements. The GDP 
Standard establishes a unified approach to the organizational process of the wholesale 
distribution of medicines and is aimed at ensuring the quality of products from the 
manufacturer to the retail network and medical institutions. It is based on the principles of 
good distribution practices adopted in the European Community and recommended by the 
World Health organization. Compliance with this standard ensures: quality and safety of 
medicinal products and medical equipment guaranteed by the manufacturer; the flow of 
medicines, medical equipment and medical products without changing their properties in the 
retail network and the retail health organizations. The purpose of the standard is to preserve 
the quality of the product as it moves from the manufacturer to the consumer, that is why the 
GDP is fully interconnected with the updated regulation. 
2.1. Current situation on the GDP in the pharmaceutical industry 
As in the globally accepted GDP, the EU standards apply to everyone in the European 
Union who participates in the wholesale distribution of medicinal products. As mentioned 
above, GDP regulates all stages of the movement of medicines and pharmaceutical substances 
along the distribution chain - from manufacturers' warehouses to pharmacies and medical 
institutions. Its goal is to observe proper storage, transportation and distribution conditions to 
ensure the quality, safety and efficacy of medical products, as well as to prevent falsified 
medicines from entering the EU market. In addition, the Practice define a number of 
approaches to the company of distribution of medicinal products in the EU, which allow them 
to follow the movement and ensure the continuity of the distributor’s responsibility for 
maintaining the declared quality of the medicinal product
17
. In this regard, in particular, it 
establishes the mandatory metrological control of the temperature regime at the 
implementation stages, introduces the concept of a “responsible person”, whose competence 
includes the creation and maintenance of a distributor quality assurance system, work with 
reclamations and product reviews. So, for example, when complaints arise, it is necessary to 
examine the entire supply chain of goods from the manufacturer to the patient. Moreover, a 
system of bilateral audits is established both by the distributor and by the manufacturer, and in 
the opposite direction. The major aim of implementation of the GDP standard is to preserve 
medical products’ quality and integrity, provide the inhabitants of the EU countries with the 
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products which quality, pharmacological properties and claimed effectiveness remains the 
same during the delivery process from the manufacturers to patients
18
. 
Let author list below the benefits from the introduction of the GDP standards to the 
company, both in business and legal terms: The GDP introduction aligns the company’s 
business processes according to the quality assurance system, as well as let the allocate 
resources and staff efficiently. In addition, the GDP supports the brand of the company, 
ensuring trust and confidence in partners and consumers, as well as automatic compliance 
with the regulations of the country or the EU. In addition, GDP introduction improves the 
quality and safety of products and ensures the successful competition in public procurements, 
supplier selection procedures, being compliant with the legal requirements of the Member 
states.
19
 
2.2. Updated duties of the pharmaceutical companies 
The EU Directive No. 2011/62/EC introduced new obligations for wholesalers, which 
concern standards in the quality system, personnel training and hygiene, facilities and 
equipment, documentation, thus updating the Good Distribution Practice.  
The revised guidelines mostly presented the changes in the following aspects:  
 Revised risk management principles, creation of the standart operation 
documentation, process and risk management in the company; 
 Revised requirements to the premises, installations, equipment, to ensure proper 
storage and distribution of medicinal products; 
 Revised requirements to the management of complaints, returns, suspected 
falsified medicinal products and recalls of the medicinal products; 
 Revised transportation rules to protect the products against theft, loss, breakage, 
failing temperature conditions;  
 Specific rules for brokers (person involved in activities in relation to the sale or 
purchase of medicinal products)
20
. 
There are new requirements for the equipment, especially computerised systems, as 
the subchapter 3.3.1 of the Guidelines require the validation or verification of all systems that 
are proving that the system is capable to achieve the necessary results, with all the tests 
included.  The companies should also provide a document which has to state all computer 
systems used within a company and describe the principles and features of interaction of all 
these computer systems. Moreover, the hardware and equipment should also be validated and 
in case if any maintenance or change occur, the new validation and new tests should be 
performed, after which the new document has to be presented
21
.  
All the products should be checked via the national database, where the producer of 
the product has to upload the information about each package produced. When arriving to the 
wholesaler, the batch of the medicine has to be verified in order to avoid the potentially 
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falsified products in case when medicinal products arrived directly from the producer. In case 
when medicinal products, that are under the regulation of the new Directive, have been 
brought from other source, not directly from the producer or its representative, the wholesaler 
has to verify each package from the batch. All the records of verification and the potential 
threats if any have to be stored. In case of the product recall from the market, if product is 
returned or suspected - the wholesalers in the whole distribution chain have to verify (scan) 
each package of the product again. Distributors and representatives of the producers are also 
responsible for marking a package if the product is quarantined, removed from sales as a 
sample for testing, and other similar activities. In addition to all the aforementioned activities 
the wholesalers and the producers should be connected to the national database, to have 
developed documentation and standard operations on the validation of all the processes, 
systems and equipment used.  
During the operations the distributors have to manually check two safety signs which 
are mandatory to be presented on the packaging - a two-dimensional bar code or a unique 
identifier and an unauthorized opening indicator which ensures the authenticity of medical 
products in the interests of patients and enterprises, as well as strengthens the security of the 
medicines’ in supply system. All pharmaceutical companies must be connected to the 
database
22
.  
Implementation of this system in Latvia required a radical improvement in the IT 
infrastructure (computers and Internet access points) which resulted in substantial financial 
costs for manufacturers (installation of additional equipment, modernization of packaging 
lines, installation of track & trace systems), distributors and pharmacy chains (software, 
scanners, staff training). Regulatory access to the database is also a separate aspect of the 
implementation of this project and had to be agreed at the initial stages.  
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3. CASE ANALYSIS OF THE DISTRIBUTOR IN LATVIA 
In this chapter it is planned to observe the distributor in Latvia, which has been 
affected by the changes in the regulation. The company is mainly operating with the other the 
counter (OTC) medical products from Germany and Czech Republic, still it also deals with a 
number of various prescription medicines, coming directly from the producers in Slovenia. 
The company portfolio includes around 55 products, being marketed around Latvia, which 
have to be controlled under the legal framework of the updated regulation.  
During the on-boarding to the national hub, where the data is stored, and connection to 
which is obligatory, the company had to choose a technical partner, who will provide an IT 
solution to the company. During the analysis of various IT providers presented on a market, 
the company has detected that the majority of the providers offer similar cloud-based 
solutions, including the storage of all the recorded data and the connection to the national hub. 
The costs were similar; therefore, the company management preferred the cooperation with 
one of the IT companies (referred as - Developer) having developed the European server 
network and EU hub in 2011-2016. Data is kept in a database provided by the Microsoft 
"Azure" cloud service. The database is hosted in a Microsoft computer centre inside the 
European Union. Developer manages and administers the database. Access to the data is 
possible through the web application. On the one hand, this constitutes the control centre, 
which can be retrieved through a web browser (recommended: Google Chrome), on the other 
hand, the web application forms the interface to the business application (available for 
Android, Windows, iOS). The business application is installed and executed on devices (e.g. 
scanners, terminals or smartphones). Developer provides the business application in the form 
of an installation file (Windows) and/or an Android package kit file.  
Verification and decommissioning (all processes of sales, goods removement from the 
flow, is considered as decommissioning) processes can be planned, controlled, executed and 
evaluated with the application presented by the Developer. Use occurs through registered 
users of the company. The application is subdivided into two components: the control centre 
and business application. Execution of the verification and decommissioning processes occurs 
through scanning of the medicine packs using the business application. The control centre 
provides both the functionalities for administration (device management, user management, 
etc.) as well as transaction-oriented functionalities (release process for bulk transactions, 
communication with the national verification systems, etc.).  
In order to provide the compliance with the legal requirements, medicines are scanned 
individually or in a bulk with the business application in single transaction process 
verification. The employee (a user) can scan new barcodes (only 2D data matrix codes) via 
the selection in the business application on the screen of the scanning device. After scanning, 
the application communicates with the national verification system and the user receives an 
immediate report on the status of the medicine. The employees of the distributor scan the 
packages in all cases, including the theft and destruction. However, all the procedures, except 
for theft and destruction, can be cancelled in case of the reversed transaction.  
As required by the updated regulation, all historic transactions are stored in the 
archive. The structure is similar to the transaction overview. In addition, the user can set 
filters to make targeted searches for transactions. Possible filters are: GTIN, expiration date, 
product number, batch number, status, process type, date range. In the archive, data is stored 
19 
 
at most up to an age of 12 months as requested by the Directive; older data is being deleted 
automatically. 
As the company operates directly with the producer, it is necessary to perform the 
following actions:  
 To verify medical product through scanning one package per batch on the 
incoming flow, in order to secure the status; 
 To dispense through scanning (decommission) the products, when selling the 
products to the social canters, small medical assistance points, paramedic points, 
prison hospitals, social support centres. While these institutions are not able to 
finance the connection to the hub, the sellers instead of the receivers are 
responsible for the validity of the medicinal product;  
 To mark through scanning the returned medicinal products, broken medicinal 
products, medicinal products used for tests or samples
23
.  
As the number of the aforementioned transactions for the company was not high, it 
was decided to create five users for the scanning and two users in the control department. 
Taking into account that given company is operating only on the Latvian market, the national 
interface required was the Latvian National hub.  
The company selected employees for each user group. User groups are: 
 Power administrator - This administrator has full authorization across all 
locations of the entire company 
 Location administrator - This user has all necessary authorizations for a specific 
location 
 Control centre user - This user may not edit any master data but only view it. 
Furthermore, he/she may call up the transaction overview and display transaction 
 Business application user – This user has access only to the business application 
and conducts all relevant verification and decommissioning processes. 
All the software and hardware had to be validated as well. Company had to create a set 
of standard operations according to the new requirements of the inflow and outflow of goods. 
The validation documentation was purchased from the Developer, as the company was unable 
to proceed with the validity and control system tests as required by the EU regulations by 
itself. Therefore, the following documentation was transferred to the company together with 
the transfer of the application: 
1. User documentation for the control centre 
2. User documentation for the business application regarding the processes 
3. Installation documentation for administrators of the control centre and business 
application 
4. Validation documents 
As presented in the table below, the initial investment of the company was € 20,000 in 
total plus the monthly costs are € 579, which results in € 6936 per year. In addition to that, the 
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company had to invest about € 3000 in the hardware and € 2000 in the training of the 
employees, as stated above, the Developer provides only initial training. Due to the rather low 
amount of transactions, the company did not need to hire more employees or acquire 
additional assets (computers or professional scanners, costing up to € 4000 per item). 
Table 1 
Company costs 
Description Value in € Invoicing cycle 
Activation fee € 5,000 One-time 
Starter package 
Users: 5 
NMVS interface: 1
24
 
Storage location: 1 
€ 499 Monthly 
Additional services   
Users € 39 Monthly 
Interfaces for national 
systems 
€ 99 Monthly 
Storage locations € 199 Monthly 
Additional services incl.:  
- Project Management 
- Creation of Qualification 
Documents  
-Test execution 
-Initial Training 
€ 1.250 per day (12 
days in total) 
One-time 
 
Summing up, the initial investment € 25,000 and € 6936 as yearly costs are, according 
to the company data, hardly covered by the income of the company, while the majority of the 
medicines are sold directly to the state institutions with the loss or with the wholesalers 
controlling the pharmacy chains with the minimal mark-up, while the prescription medicines 
mark-up is managed and set up by the national regulations. It means that the company will 
face the necessity to cover the expenses by the changes in the OTC medicinal products’ prices 
introducing the financial pressure on producers, distributors and end users. In the next 
chapter, the challenges and problems will be analysed, based on the experience of the 
company in this case analysis.  
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4. POSSIBLE CONFLICTS AND PROBLEMS DURING THE IMPLEMENTATION OF 
THE NEW FALSIFIED MEDICINAL PRODUCTS’ DISTRIBUTION PREVENTION 
REGULATION 
4.1. Challenges pharmaceutical companies and another distributors 
face 
Firstly, let author analyse the information, acquired from the company from the 
previous chapter, while conducting the company performance analysis. In the last months of 
operation, the company faced a number of problems: 
1) Failure of the EU hubs performance. In the first month when the regulation came in 
force, the European Union IT infrastructure was detected as not ready to perform correctly 
with given number of transactions and users. The hub was offline part of the time, meaning 
that the national verification systems were not able to connect to the hub in the order to check 
and exchange the information, the producers could not upload the necessary data, as well as 
the distributors were almost not able to check or dispense the medicinal products. 
Disregarding the fact that this issue was unpleasant, it was mostly solved by the producers and 
distributors, who have predicted the possibility of the system failure and hedged the risks by 
ordering, producing and importing the medicinal products before the 09th of February, to 
secure availability of necessary medicinal products on stock for one or two months ahead, 
until the IT issues would be solved. However, the drop in sales was already noted, as while 
the producers were trying to comply with the requirement they were not able to move the 
goods in a regular amount, therefore the financial ratios also dropped
25
.  
2) Update of the documents. In order to comply with the renewed GDP requirements 
and new requirements set by Directive on the prevention of the falsified medicinal products, 
the companies had to update all the standard operations and other documents. All the 
documents were formed according to the international and national norms. Taking into 
account that the national norms were not accepted until the beginning of 2019, the vast 
number of companies had to update their documents twice, first time documents were 
prepared according to the new international regulations and second time, according to 
somewhat tightened national norms.  
3) The technical impossibility of applying an individual code. It was a problem for the 
number of producers to apply the code to existing packaging due to its small size or 
inappropriate shape. This resulted in the wrong placement and disability of the distributor to 
scan the package in an ordinary way. Moreover, scanning of each package is time-consuming, 
adding to this a fact that the response from the European hub is slow and it takes time to 
receive an appropriate report, using new system the time of operations increased almost twice. 
In the way to ease the scanning procedure, the companies have to invest in professional 
scanners as well as create additional space for the scanning with the appropriate lighting, that 
will consequently affect the documents and standard operations.  
4) Scanning failures. This issue was claimed to be the most serious and risky and is 
investigated by the national and EU agencies. Part of the uploaded data by the producers is 
not correctly represented on the international and/or national data storage levels. This occurs 
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due to the lack of several features, that in some repositories are mandatory, but in others - are 
not, as well as due to the technical misclicks and similar issues. These cases are consequent 
and are repeating almost every week, urging the distributors to move the packages to the 
quarantine area and not being able either to return, or to sell the medicinal products, even 
despite the fact that the medicinal products are not falsified, are approved by laboratory, and 
even in case of the reimbursed medicines or medicines for the hospitals, that are urgently 
needed for patients in critical conditions. Trying to solve these issues the companies were 
usually reported that the problem is on the data repository level and the companies have to 
quarantine the product until a problem is solved. This occurs also due to the challenge for the 
manufacturers to report on the volume of production of medicines in advance and buy the 
unique codes for each batch from the European hub, which is not always possible in the 
conditions of market volatility and demand for it.  
Furthermore, it is necessary to present some other issues, that have been experienced 
by the representative offices of various brands in Latvia, other distributors and pharmacies.    
One of the small pharmacy company reported, that as soon as the company was not a 
part of any big pharmaceutical holding (the number of pharmacies in the company is three), it 
had to follow the changes in the regulations by itself. The major problem for the 
implementation of the new requirements was the lack of information for the company. After a 
number of meetings with the Latvian National Medicine Verification Agency it was 
concluded, that every pharmacist of the pharmacies has to verify every package upon arrival 
from the distributor to check the validity of the package. Similarly, when selling the package 
to the end customer, the employee has to scan (dispense) the package. The company could use 
the opportunity to verify the medicine only in one of three pharmacies, but the companies did 
not have a common logistics system, therefore each of the pharmacies had to separately 
manually enter the information about each package having entered in the circulation by itself.  
This increased the working time of the employees and created the necessity to hire additional 
staff, also, scanning via mobile devices in the pharmacies is not acceptable due to the time 
constraints, therefore the professional scanners were purchased. Taking into account the fact, 
that the monthly turnover of the company is less then 15 thousand euro, and the total 
investments in new system with activation fee of more than 20 thousand euro lead to question 
if existence of this type of small pharmacy chains are reasonable. 
Next, the responsibility for the small medical assistance centres and other social 
centres, that cannot afford such huge investments seems to be biased. The state is unable to 
support social institutions and transfer the responsibility to the business sector, whose 
payments form the budget for the social establishments. Moreover, the small pharmacies and 
private companies are not able to comply with all requirements as well, up to now, no specific 
measures have been introduced to assist.  
4.2. Legal conflicts 
Taking into account the issues mentioned in subchapter 6.1, the importers and 
responsible institutions are unable to ensure the presence of the medicines on the market 
timely. To discuss this situation in terms of the possible legal conflicts, let author first present 
the legal framework behind the rights of the patients. According to the Universal Declaration 
of human rights set by the United Nations, every person, as a member of society, has the right 
to social security and to exercise the rights necessary for maintaining his dignity and for the 
free development of his personality in the economic, social and cultural fields through 
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national efforts and international cooperation and in accordance with the structure and 
resources of each state. This was followed by the consequent adoption of the Universal 
Declaration of Human Rights
26
 and also in 1950 by the signature of the European Convention 
of Human Rights
27
.  Next, let author consider the legislation considering the responsibilities 
and duties of the states. In 1978 the Declaration of Alma-Ata stated that states have a 
responsibility for the health of the citizens and people living on the territory
28
, which can be 
fulfilled only by the provision of adequate health and social measures. In 1994 the Declaration 
on the promotion of patient’s rights in Europe29 by WHO was published, stating that 
“everyone has the right to receive such health care as is appropriate to his or her health needs, 
including preventive care and activities aimed at health promotion. Services should be 
continuously available and accessible to all equitably, without discrimination and according to 
the financial, human and material resources which can be made available in a given society”.  
As to the EU legislative framework, then it is possible to state Convention for 
Protection of Human Rights and Dignity of the Human Being with Regard to the Application 
of Biology and Biomedicine: Convention of Human Rights and Biomedicine, Council of 
Europe as the one of the primary documents, that Latvia has ratified in 2010. The Convention 
is the first legally binding international text aimed at protecting human dignity, rights and 
freedoms by adopting a number of principles and prohibitions against the misuse of the 
achievements of biology and medicine
30
. The starting point of the Convention is that human 
interests are above the interests of science or society. The Convention sets out a number of 
principles and prohibitions in relation to genetic and medical research, consent, the right to 
privacy and information, transplantation, public discussion, etc. The Convention prohibits all 
forms of discrimination based on genetic heritage and permits genetic testing for medical 
purposes only. It permits genetic engineering only for prophylactic, diagnostic, or therapeutic 
purposes, and only on condition that such engineering is not aimed at changing the genome of 
the heirs of a given person. The Convention prohibits the use of technologies aimed at 
providing medical assistance in procreation in order to choose the sex of the future child, 
unless this is done to prevent the child from inheriting a serious disease. 
The Convention establishes the rules of medical research, listing their detailed specific 
conditions, especially for those who are unable to consent to such research. It is forbidden to 
create human embryos for research purposes, and when a country allows research on embryos 
in vitro, adequate protection of these embryos must be provided. 
The Convention also establishes the principle that a person must give the necessary 
consent for medical intervention in an explicit form and in advance, with the exception of an 
emergency. Such consent may be freely refused at any time. Medical intervention for persons 
unable to consent to it, such as children and those suffering from a mental disorder, can only 
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be carried out in cases where it can have a real and direct positive effect. Convention 
provides, that each patient has the right to familiarize themselves with information about his 
state of health, including information about the results of genetic testing. However, it 
recognizes the rights of the patient not to be informed about this. The Convention prohibits 
the removal of organs and other tissues from persons who are unable to give appropriate 
consent. The only exception is allowed under certain conditions for the removal of 
regenerating tissues (especially bone marrow), when the recipient is a brother or sister of the 
donor. The Convention recognizes the importance of promoting public debate and proper 
consultation on the above issues. The only restrictions may be prescribed by law and be 
necessary in a democratic society in the interests of public peace, the prevention of crime, the 
protection of public health and the rights and freedoms of others.  
Consequently, to the Convention, in order to ensure a high level of protection of 
human health and a high level of service in European medical institutions, as early as 2002, 
the European Charter of Patients' Rights was prepared. It defines 14 basic rights of every 
person, therefore, they must be recognized and respected in every state. Rights are related to 
the duties and responsibilities that patients and caregivers must assume. The Charter can be 
used as a way to initiate patient rights protection activities, consisting of both prevention of 
rights violations and remedial measures
31
. Such activities, along with the courts, can be 
carried out by active civil organizations, official institutions and bodies - for example, 
ombudsmen, ethical committees or alternative dispute resolution commissions
32
.  
Nys and Goffin (2011) identify three types of patients’ rights: basic, such as privacy, 
social, such as reimbursement and access to health care, as well as consumer-based, such as to 
choose the provider of treatment
33
. In addition to the mentioned before, the authors stated that 
patient’s rights have developed in Latvia since 2010, when the Patients’ rights office has been 
developed. Disregarding the fact that the law concerned some of the issues already since 
1997, the Patient’s Rights law came into force in 201034. The purpose of the law is to promote 
a positive relationship between the patient and the health care provider by promoting the 
patient's active participation in their health care, as well as to enable him / her to exercise and 
defend their rights and interests. This law on the national level assumes the patient has the 
right for a timely treatment. The medical institution at which the patient has contacted 
provides information on the possibilities and terms of receiving the treatment, as well as on 
other medical institutions where appropriate treatment can be obtained. The aforementioned 
law together with the Medical treatment law form the basis for the fulfilment of the basic 
rights of the patient
35
.  
Social rights, in line with the Directive 2011/24/EU of the European Parliament and of 
the Council of 9 March 2011 on the application of patients’ rights in cross-border 
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healthcare
36
, about the financing, access and reimbursement, are provided by the Cabinet of 
Ministers Regulations Nr. 899
37
 on the procedure for reimbursement of the costs of 
purchasing medicinal products and medical devices for outpatient treatment as well as the 
Health Care Financing Law of Latvia
38
. The reimbursement procedure includes a set of 
measures that enable the patient to purchase medicines and medical devices, the purchase of 
which, in accordance with the regulations, is partly or fully covered by the funds allocated for 
reimbursement of drug purchase expenses for the current year. The aim of the compensatory 
measures is to provide medicines and medical devices to as wide a range of patients as 
possible within the funds allocated for reimbursement, as well as to channel the lowest 
possible price and cost savings for compensated medicines and medical devices to improving 
patients' health and achieving treatment goals. The cost of purchasing medicinal products and 
medical devices shall be borne in full by the State for the patient who is recognized as poor or 
as an asylum seeker in accordance with the procedures prescribed by regulatory enactments, 
and who is entitled to reimbursement of the costs of purchasing medicinal products or medical 
devices
39
. Taking into account the aforementioned issues and the second chapter of the thesis, 
the following legal conflicts arise:  
 Patient’s rights violations  
 Conflict of interests in terms of GDP 
Let author next elaborate on both issues in details to drive conclusions about the 
possible impact on the legal conflicts of the new prevention regulation.  
For a start, it is necessary to note the possible conflict that arises from the violation of 
the rights of patients. As mentioned earlier, incorrect or incorrectly functioning system of 
validation of medicinal products lead to the fact that distributors or manufacturers are not able 
to deliver to the market those products that are not validated by the new system. This happens 
even if all certificates and laboratory tests are available - the product must be quarantined 
until the failure is completely eliminated and can be sold only with a positive response from 
the system, responsible for the verification of the medicinal product. One more to point out is 
the fact, that the products, that are controlled and tested by the new regulation is the 
prescription medicines. The prescription is the official prescription of the medicinal product in 
the prescribed form, issued by an eligible medical employee for the purpose of dispensing the 
finished medicinal product. As soon as prescription medicinal products are usually more 
concentrated as well as very specifically used, they are strictly controlled by the government. 
This means that prescription medicinal products are quarantined, which delays the delivery of 
controlled products to the market in a timely manner. It is necessary to take into account the 
fact that neither the manufacturers nor the distributors are able to urgently produce or store 
huge quantities of goods. As a result, since the state controls and monitors prescription 
medicinal products and their movement, there is a shortage of one or another drug in the 
market due to quarantine. In addition, many of the prescription medicinal products are 
included in reimbursable medicinal products or medicinal products procured for the needs of 
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emergency care and hospitals. It should be emphasized that hospitals and government 
institutions operate on the principle of public procurement. Accordingly, by announcing the 
public procurement and concluding an agreement with the supplier, the hospital or institution 
cannot quickly purchase a similar product in the event of force majeure. Accordingly, a 
number of problematic situations arise in connection with the quarantine: first, medicinal 
products for patients from the reimbursement list are not available in a timely manner, and 
similar ones are available for for additional payment; secondly, medicinal products for 
hospitals, prisons and other social and state institutions responsible for treating the population 
are not available in a timely manner; thirdly, medicinal products are not available, which 
should be delivered on time according to the public procurement contracts. In such situation, a 
violation of a number of patients' rights occurs, as well as a conflict of interests and restriction 
of the distributor’s freedom. In this case, the basic rights of the patient are violated, while the 
patient cannot choose the therapy or medicinal product, cannot choose the treatment, he is 
facing the limited choice. In addition, the social right of the patient is limited. The patient 
cannot claim reimbursement in the required amount, he is obliged to invest personal financial 
resources in order to continue therapy, and in case of a shortage of financial resources his 
right to access health care is limited. Similarly, the social rights of patients who are admitted 
to hospitals, where there are no medications to be provided by the state, are limited. 
Consumer-based rights of the patient are also violated, while the patient has to choose the 
provider of the therapy, who is able to provide the medicinal product, while the access to the 
medicinal products are not equal. The patient cannot choose the pharmacy, while in case of 
the computer failures, he has to choose the pharmacy with the more updated technical 
support, otherwise the medicinal products cannot be dispensed.  
In addition, there is a conflict of interest between the manufacturer, state buyers, 
distributors and patients. Medical institutions that have concluded a contract with distributors 
have the opportunity to claim compensation or a fine if the goods are not delivered. In turn, 
when the verification system fails, the distributor does not have the right to make deliveries, 
but this happens not through his fault, but because of failures in the international information 
system. Accordingly, a situation where the distributor may incur losses arises, the hospital 
incurs losses and does not fulfil obligations to patients, and the rights of patients are limited. 
Such situations impose an additional financial burden on the distributor, together with losses 
and a heightened profit, which he incurs because of the impossibility of selling goods. 
Violations of patient’s rights or lack of attention to them can have serious health 
consequences. Such type of the hidden discrimination in healthcare is a powerful barrier to 
access to health services and affects their quality.  
The second point that needs to be considered is a possible conflict of interest within 
the framework of the requirements of good distribution practice. This is another challenge 
distributors and medicinal products manufacturers meet. Any quarantine means constant 
communication with the responsible authorities for a quick solution to the problem. 
According to the standards of good distribution practices laid down in its fundamentals, the 
distributor can distribute in the interests of the public, provided that he is confident in 
compliance with the quality and all documentation required is present in the necessary form. 
Accordingly, subject to obtaining the necessary results of laboratory tests, certificates of 
production, and other data, the distributor can distribute the goods. However, on the other 
hand, even with the confidence of the validity of the medicinal products, the distributor 
cannot sell or transfer the medicinal products, since the medicinal products are incorrectly 
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displayed in the verification system. At this stage, most manufacturers and distributors put 
new regulations above the requirements of good practice, which requires further 
consideration. 
In addition, work in accordance with good distribution practices, provides clearly 
marked movement of goods according to certain warehouse and logistics principles (e.g. first 
in - first out). It is stipulated that quarantine takes a long time, respectively, quarantine zones 
are far away in order to avoid goods mixing, as well as placing in quarantine requires the 
development of documentation and change of logistic processes. There is no concept of short-
term quarantine, since the quarantine process is also regulated by pharmaceutical rules. 
However, new requirements do not provide for any other exclusion of goods from circulation, 
except by placing them in the quarantine zone. In turn, problems are often solved within one 
to two working days. Accordingly, since the company must follow the standards, a lot of 
additional processes are launched and carried out. Often such processes are completely 
unnecessary, while the company spends additional time and financial resources. 
All of the above creates a conflict between the regulations of the pharmaceutical 
industry, the rights of patients and the new legislation. Insufficient preparation of the 
transition in Latvia has led to restrictions on the delivery of goods to the market and the 
inability to acquire them by patients. 
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CONCLUSIONS 
After having conducted the research the author came to the following conclusions 
answering the research questions stated.  
[RQ1]: What are the background and benefits of the new European Union prevention 
regulation of the entry into legal supply chain of falsified medicinal products?   
1. At the beginning of the new century, the previously existing regulations regarding 
the marketing of the medicinal products were revised and replaced by a single 
code by the Directive 2001/83/EC of 6 November 2001.  
2. The directive laid down all the fundamental principles of market entry 
(registration), production and pharmacovigilance of registered medicinal products, 
especially for human use. Exactly this directive created the basis for the existing 
updated regulation on the falsified medicinal products for human use, while it 
contained the fundamental standards for confirming safety and efficacy, as well as 
the need to prove a positive balance between the benefits and risks of a drug. Still, 
as a result, there was a necessity on the even more detailed regulation of the 
medicinal products, that is why the Directive was amended step by step in the 
majority of the aspects, providing new grounds and finally the specific new 
regulation was introduced in 2011.  
3. According to the new European Union prevention regulation of the entry into legal 
supply chain of falsified medicinal products, all EU member states are obliged to 
bring their own legislation and trade practices in line with the requirements of this 
directive until February 9, 2019. It is important to note, while the updated 
requirements implied that protection against the falsification of the medicinal 
products is carried out by applying a special unique number on the packaging, 
which will allow to distinguish falsified medicinal products from the original ones, 
since the unique number of each package can be checked at any time using a 
special database on the European and national levels.  
4. Falsified medicinal products have to be quickly detected and removed from traffic 
without incident. Manufacturers who do not have such a tracking solution will 
have to withdraw their products from the European market. The tightening of 
regulations, dictated by the fight against falsification of medicinal products, 
requires measures of maximum security throughout the supply chain in the 
manufactures of pharmaceutical products that is beneficial for the patients, while 
each participant in the supply chain can provide information about the origin of the 
medicinal product and its further movement. Thus, producers and distributors must 
themselves control and identify to whom they supply and from whom they 
purchase products throughout the entire chain. 
[RQ2]: What are the updated or newly created duties of the pharmaceutical products 
distributors?  
5. The EU Directive No. 2011/62/EC introduced new obligations for wholesalers, 
which concern standards in the quality system, personnel training and hygiene, 
facilities and equipment, documentation, thus updating the Good Distribution 
Practice. There are new requirements for the equipment, especially computerised 
systems - the validation or verification of all systems that are proving that the 
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system is capable to achieve the necessary results is required, with all the tests 
included.   
6. The companies should also provide a document which has to state all computer 
systems used within a company and describe the principles and features of 
interaction between these computer systems. Moreover, the hardware and 
equipment should also be validated and in case if any maintenance or change 
occur, the new validation and new tests should be performed, after which the new 
document has to be presented.  
7. All the products should be checked via the national database, where the producer 
of the product has to upload the information about each package produced. When 
arriving to the wholesaler, the batch of the medicine has to be verified in order to 
avoid the potentially falsified products in case when medicinal products arrived 
directly from the producer.  
8. All the records of verification and the potential threats if any have to be stored. In 
case of the product recall from the market, if product is returned or suspected - the 
wholesalers in the whole distribution chain have to verify (scan) each package of 
the product again. Distributors and representatives of the producers are also 
responsible for marking a package if the product is quarantined, removed from 
sales as a sample for testing, and other similar activities. Implementation of this 
system in Latvia required a radical improvement in the IT infrastructure 
(computers and Internet access points) which resulted in substantial financial costs 
for manufacturers (installation of additional equipment, modernization of 
packaging lines, installation of track & trace systems), distributors and pharmacy 
chains (software, scanners, staff training).  
9. In order to provide the compliance with the legal requirements, medicines are 
scanned individually or in a bulk with the business application in single transaction 
process verification. In order to comply with the renewed GDP requirements and 
new requirements set by Directive on the prevention of the falsified medicinal 
products, the companies had to update all the standard operations and other 
documents. All the documents were formed according to the international and 
national norms. 
[RQ3]: What are the conflicts and problems pharmaceutical products distributors face 
while implementing the new requirements set by the updated regulation?  
10. Distributors face the failure of the EU hubs performance, while in the first month 
when the regulation came in force, the European Union IT infrastructure was 
detected as not ready to perform correctly with given number of transactions and 
users.  
11. Distributors face the technical impossibility of applying an individual code. It was 
a problem for the number of producers to apply the code to existing packaging due 
to its small size or inappropriate shape. This resulted in the wrong placement and 
disability of the distributor to scan the package in an ordinary way.  
12. Distributors face the scanning failures. This issue was claimed to be the most 
serious and risky and is investigated by the national and EU agencies. Some of the 
uploaded data by the producers is not correctly represented on the international 
and/or national data storage levels. This occurs due to the lack of several features, 
that in some repositories are mandatory, but in others - are not, as well as due to 
the technical misclicks and similar issues. These cases are consequent and are 
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repeating almost every week, urging the distributors to move the packages to the 
quarantine area and not being able either to return, or to sell the medicinal 
products, even despite the fact that the medicinal products are not falsified, are 
approved by laboratory, and even in case of the reimbursed medicines or 
medicines for the hospitals, that are urgently needed for patients in critical 
conditions.  
13. Distributors are obliged to invest in the new equipment, training, as well as 
connection to the national databases, that is hardly covered by the income of the 
companies, while the majority of the medicines are sold directly to the state 
institutions with the loss or with the wholesalers controlling the pharmacy chains 
with the minimal mark-up, while the prescription medicines mark-up is managed 
and set up by the national regulations. It means that the company will face the 
necessity to cover the expenses by the changes in the OTC medicinal products’ 
prices introducing the financial pressure on producers, distributors and end users. 
14. Incorrect or incorrectly functioning systems of validation of medicinal products 
lead to the fact that distributors or manufacturers are not able to deliver to the 
market those products which are not validated by the new system. Consequently, 
medicinal products for patients from the reimbursement list are not available in a 
timely manner, and similar ones are available for money; secondly, medicinal 
products for hospitals, prisons and other social and state institutions responsible for 
treating the population are not available in a timely manner; thirdly, medicinal 
products are not available, which should be delivered on time according to the 
public procurement contracts. In such a situation, a violation of a number of 
patients' rights occurs, as well as a conflict of interests and restriction of the 
distributor’s freedom. In this case, the basic rights of the patient are violated, while 
the patient cannot choose the therapy or medicinal product, cannot choose the 
treatment, he faces the limited choice. Moreover, the patient cannot claim 
reimbursement in the required amount, he is obliged to invest personal financial 
resources in order to continue therapy, and in case of a shortage of financial 
resources his right to access health care is limited. Similarly, the social rights of 
patients who are admitted to hospitals, where there are no medications to be 
provided by the state, are limited. Finally, the patient has to choose the provider of 
the therapy, who is able to provide the medicinal product, while the access to the 
medicinal products are not equal. The patient cannot choose the pharmacy, while 
in case of the computer failures, he has to choose the pharmacy with the more 
updated technical support, otherwise the medicinal products cannot be dispensed. 
15. Distributors face a conflict of interest between the manufacturer, state buyers, 
distributors and patients. Medical institutions that have concluded a contract with 
distributors have the opportunity to claim compensation or a fine if the goods are 
not delivered. In turn, when the verification system fails, the distributor does not 
have the right to make deliveries, but this happens not through his fault, but 
because of failures in the international information system. Accordingly, a 
situation arises that the distributor may incur losses, the hospital incurs losses and 
does not fulfil obligations to patients, and the rights of patients are limited. Such 
situations impose an additional financial burden on the distributor, together with 
losses and a heightened profit, which he/she incurs because of the impossibility of 
selling good. 
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